Table 1.
Experimental design and kidney function 1 week after transplant1
| Group | Transfusion | Transplant | Immunosuppression | BUN (mg/dL) | Scr (mg/dL) |
|---|---|---|---|---|---|
| Control (C) | − | − | − | 21.90 ± 2.37 | 0.32 ± 0.08 |
| Transfusion alone (Tn) | + | − | − | 21.46 ± 1.38 | 0.24 ± 0.14 |
| Transplant + CsA (TxCsA) | − | + | CsA (10 mg/kg/day × 7 days) | 39.42 ± 9.322 | 0.57 ± 0.222 |
| TnTxCsA | + | + | CsA (10 mg/kg/day × 7 days) | 51.80 ± 12.952 | 0.76 ± 0.312 |
| Tx | − | + | − | 253.27 ± 46.052 | 3.97 ± 1.202 |
| TnTx | + | + | − | 54.42 ± 15.032 | 1.03 ± 0.502 |
BUN, blood urea nitrogen; Scr, serum creatinine. Normal range: BUN = 9–21 mg/dL; Scr = 0.1–0.6mg/dL.
Study design; animal model of acute antibody-mediated rejection; 500 μL of donor (Brown Norway (BN), RT1n) blood was drawn into a heparinized syringe, and then injected intravenously into a recipient (Lewis, RT1I) rat. Three weeks later, recipients received a transplant from a BN rat, in conjunction with bilateral kidney nephrectomy. In some groups, animals were given 10 mg/kg cyclosporine A (CsA 10 mg/ kg/day) to mitigate cellular rejection.
Control and transfusion alone (Tn) groups were not transplanted. In these groups, kidney function was measured 4 weeks after study enrollment (control group) or 4 weeks after blood transfusion (Tn group).
p < 0.02 compared with C and Tn.